0QIU.LSE Novo Nordisk A/S Class B

Commercial Services & Supplies London Exchange
8.24 DKK
Close of Mar 11, 2026
214.33 391.24
Market cap
DKK 19.9B
P/E
0.4x
P/B
-
ROE
-
Dividend yield
108.15%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2022.

Is 0QIU.LSE undervalued?

Graham number

The Graham number of Novo Nordisk A/S Class B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novo Nordisk A/S Class B fundamental analysis

No fundamental analysis for Novo Nordisk A/S Class B yet.

Novo Nordisk A/S Class B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novo Nordisk A/S Class B

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of hae…

Full company profile